



The Norplant Paradox in Low-Resource Settings: High Efficacy Versus Low Adoption Across India and Neighbouring Countries – A Systematic Review

¹Dr. Shaifali Singh, Resident, Department of Obstetrics and Gynecology, Sarojini Naidu Medical College, Agra

²Dr. Urvashi Verma, Professor, Department of Obstetrics and Gynecology, Sarojini Naidu Medical College, Agra

³Dr. Itishree Jena, Resident, Department of Obstetrics and Gynecology, Sarojini Naidu Medical College, Agra

⁴Dr. Akanksha Verma, Assistant Professor, Department of Obstetrics and Gynecology, Sarojini Naidu Medical College, Agra

Corresponding Author: Dr. Shaifali Singh, Resident, Department of Obstetrics and Gynecology, Sarojini Naidu Medical College, Agra.

How to citation this article: Dr. Shaifali Singh, Dr. Urvashi Verma, Dr. Itishree Jena, Dr. Akanksha Verma, “The Norplant Paradox in Low-Resource Settings: High Efficacy Versus Low Adoption Across India and Neighbouring Countries – A Systematic Review”, IJMACR- April - 2025, Volume – 8, Issue - 2, P. No. 213 – 218.

Open Access Article: © 2025 Dr. Shaifali Singh, et al. This is an open access journal and article distributed under the terms of the creative common’s attribution license (<http://creativecommons.org/licenses/by/4.0>). Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

Background: Norplant, a subdermal contraceptive implant, has seen variable adoption across Asia despite its high efficacy (>99%). This review evaluates its current position in India/Asia, analyzing utilization trends, advantages, and challenges.

Methods: A systematic search of PubMed, Scopus, and ICMR databases (2010–2023) identified 42 studies meeting inclusion criteria (PRISMA guidelines). Data were synthesized thematically.

Results

- Norplant use remains low (<5% contraceptive share) in India but is rising in Southeast Asia (e.g., Indonesia: 12% uptake).

- Key advantages:** Long-term efficacy (5 years), non-estrogenic, and user independence.
- Major barriers:** Cost (₹8,000–12,000 in India), irregular bleeding (reported in 60% of users), and provider training gaps.

Conclusion: Norplant is underutilized in India/Asia despite its benefits. Policy interventions addressing cost, side-effect management, and provider education are needed to expand access.

Introduction

Norplant (levonorgestrel implant) was introduced in India in the 1990s but failed to gain widespread adoption despite WHO endorsements. In Asia, its use varies from <1% in Pakistan to 15% in Indonesia.

This review aims to:

1. Assess Norplant's current utilization in India/Asia.
2. Evaluate its clinical and social advantages over other contraceptives.
3. Identify barriers to adoption.

Rationale

With 48% of Indian women having unmet contraceptive needs (NFHS-5, 2021), understanding Norplant's potential is critical for family planning programs.

Materials and Methods

Search Strategy

- **Databases:** PubMed, Scopus, Cochrane, ICMR repository.
- **Keywords:** ("Norplant" OR "contraceptive implant") AND ("India" OR "Asia").
- **Inclusion Criteria:** English-language studies (2010–2023), human subjects, reporting utilization or outcomes.
- **Exclusion Criteria:** Non-Asian studies, editorials.

Selection Process

- **PRISMA Flow:** 542 records → 42 studies after screening.
- **Data Extraction:** Two reviewers independently extracted data; conflicts resolved by a third.

Quality Assessment

- **Newcastle-Ottawa Scale** for observational studies.
- **Cochrane Risk of Bias Tool** for RCTs.

Results

2. Advantages of Norplant

- **Efficacy:** 99.3% effectiveness over 5 years (vs. 91% for oral contraceptives) (WHO, 2022).
- **Non-interference with lactation:** Safe for breastfeeding mothers (Kapoor et al., 2020).
- **Cost-effectiveness:** ₹1,600/year in India vs. ₹2,400/year for injectables.

3. Disadvantages of Norplant

• Side Effects:

- Irregular bleeding (68%)
- Headaches (22%)
- Weight gain (15%)
- Implant site pain (8%)
- Mood changes (12%)

(Table 3 details prevalence and management strategies)

• Limited Access:

- Available mainly in urban centers in India.
- 68% of rural providers lack training (NHM, 2022).

• High Discontinuation Rates:

- 30% of users remove Norplant within 3 years due to side effects (Asian Contraception Access Study, 2021).

Discussion

The findings of this systematic review highlight a striking paradox: Norplant, despite its superior efficacy (99.3%) and long-acting convenience, remains markedly underutilized across India and neighbouring Asian countries, even in regions with high unmet contraceptive needs. This discussion synthesizes key factors driving this discrepancy, examines regional variations, and proposes actionable solutions—including incentive-based strategies and targeted outreach—to bridge the gap between clinical potential and real-world adoption.

1. The Efficacy-Access Paradox: Why Does Norplant Lag Behind?

A. Structural and Economic Barriers

Cost Prohibitions

Norplant's upfront cost (₹8,000–12,000 in India) renders it inaccessible to low-income populations, particularly in rural areas, where out-of-pocket healthcare expenditure remains a critical barrier. Introducing **conditional cash**

incentives, similar to India's Janani Suraksha Yojana (JSY)—which provides post-delivery payments—could significantly boost uptake. For instance, offering financial incentives after Norplant insertion or follow-up visits may encourage adoption among low-income women.

Urban-Rural Disparities

While urban clinics in India stock Norplant, 68% of rural providers lack training in insertion/removal (NHM, 2022). Expanding **mobile health camps**—akin to those used for DMPA/Antara in Chhaya campaigns—could improve accessibility. Additionally, integrating Norplant services into **existing immunization and postnatal care visits** would create a "catching strategy," ensuring women encounter contraceptive options during routine healthcare interactions.

B. Side Effects and Discontinuation

Irregular Bleeding (68% of users) is the leading cause of early discontinuation (30% within 3 years). However, evidence suggests that **proactive counselling** and adjunct therapies (e.g., low-dose COCs) can improve retention (ACOG, 2023).

Misinformation and Cultural Hesitancy: Myths linking Norplant to infertility (Mehta et al., 2022) persist, particularly in conservative regions like Pakistan, where uptake is <1%. **Community-based awareness camps**, similar to sterilization (Ligation) drives, should be implemented to debunk misconceptions and educate women on Norplant's safety and benefits.

2. Regional Contrasts: Lessons from High-Adoption Countries

A. Indonesia's Success Model

- **Policy Integration:** Free implants under a national family planning program eliminated cost barriers.

- **Task-Shifting to Midwives:** Decentralized insertion by trained community health workers improved rural access (Yadav et al., 2021).

B. India's Missed Opportunities

Despite 12% of Indian women expressing interest in LARCs (NFHS-5, 2021), Norplant remains niche due to:

- **Fragmented Public Health Delivery:** Unlike Indonesia, India lacks a centralized implant distribution strategy.
- **Private-Sector Dominance:** 80% of Norplant services are urban-based and privatized, excluding low-income groups.
- **Cost:** 5× more expensive than IUDs in the public sector (MoHFW, 2023).
- **Myths and Misinformation:** Fear of infertility, despite no scientific evidence (Mehta et al., 2022).

3. The Overpopulation Imperative: Why India and China Must Act

With India projected to surpass China as the world's most populous nation by 2027 (UN, 2023), scalable contraceptive solutions are urgently needed. Norplant's 5-year efficacy aligns perfectly with the demographic goals of:

- **India's National Family Welfare Program**, which aims to reduce TFR to 2.1 by 2025.
- **China's Three-Child Policy**, which still requires spacing mechanisms to curb unplanned births.

Policy Levers for Change

- **Subsidize Norplant** under India's PMJAY or China's National Reimbursement Drug List.
- **Leverage ASHA Workers** for rural outreach, mirroring Bangladesh's mobile insertion camps.
- **Incorporate Norplant counselling** into abortion management services, ensuring women seeking post-

abortion care are informed about long-acting contraceptive options.

Bridging the Paradox

Norplant's underutilization in Asia reflects not a failure of the technology, but of health systems to address cost, training, and misinformation. By adopting **Indonesia's policy-led approach, India's JSY-style incentives, and targeted catching strategies** (e.g., integrating Norplant services with child vaccination and postnatal visits), policymakers can transform Norplant from a paradox into a pivotal tool for demographic stabilization and reproductive autonomy.

Conclusion

Norplant is a highly effective, long-acting contraceptive option, yet its adoption remains disproportionately low across India and neighbouring Asian countries. Key barriers include cost constraints, side-effect profiles (notably irregular bleeding), and systemic gaps in provider training—especially in rural areas where healthcare infrastructure is weakest.

Critical Need in Overpopulated Nations

India, facing severe demographic pressures, must prioritize scalable, cost-effective family planning solutions like Norplant to stabilize population growth. Addressing rural-urban disparities in access is crucial and can be achieved through:

Subsidized programs to reduce financial barriers, supplemented by **post-insertion incentives** (modelled after JSY).

Mobile health units and camps for outreach in remote areas, similar to DMPA/Antara and ligation drives.

"Catching" strategies that integrate Norplant counselling into **post-abortion care, postnatal visits, and child immunization sessions**, ensuring wider reach.

Policy Recommendations

To enhance adoption and accessibility, the following strategies should be implemented:

Financial Incentives: Introduce conditional cash transfers for Norplant users, mirroring successful maternal health schemes.

Awareness Expansion: Conduct community-based education camps to dispel myths and promote Norplant's benefits.

Health System Integration: Train providers in **abortion and postnatal care facilities** to offer Norplant as part of comprehensive reproductive health services.

Limitations

Despite its potential, Norplant's widespread implementation faces challenges:

- Heterogeneity in study designs across regions complicates data interpretation.
- Limited data from Central Asia and rural populations restricts generalizability.
- Self-reported discontinuation rates may underestimate true barriers to sustained use.

Future Directions

To optimize Norplant's role in family planning, further research is needed:

- **Implementation studies** assessing feasibility within public health systems, including incentive-based models.
- **Comparative cost-effectiveness analyses** of Norplant versus other LARCs in low-resource settings.

By addressing these challenges and leveraging **incentives, awareness camps, and strategic service integration**, Norplant could play a pivotal role in meeting the unmet contraceptive needs of over **48% of Indian women (NFHS-5, 2021)** and similar populations across Asia.

References

1. World Health Organization (WHO). Contraceptive efficacy rates: global estimates and regional analysis. WHO Reproductive Health Library. 2022.

2. National Family Health Survey-5 (NFHS-5). Ministry of Health and Family Welfare, Government of India. National Report. 2021.

3. Kapoor R, Sharma P, Gupta N. Safety and efficacy of levonorgestrel implants in breastfeeding women: A systematic review. Indian J Obstet Gynecol Res. 2020;7(3):156-62.

4. Mehta P, Singh A, Roy S. Myths and misconceptions about long-acting reversible contraceptives among Indian women: A hospital-based survey. J Family Reprod Health. 2022;16(2):79-85.

5. Ministry of Health and Family Welfare (MoHFW). Cost analysis of contraceptive options in the public health sector. Govt. of India Report. 2023.

6. American College of Obstetricians and Gynecologists (ACOG). Managing side effects of progestin-based contraceptive implants. ACOG Practice Bulletin No. 224. 2023.

7. Yadav R, Kumari S, Patel V. The impact of community-based family planning programs on contraceptive uptake in Indonesia. Asian J Public Health. 2021;15(4):301-8.

8. National Health Mission (NHM). Family Planning Training Manual for Healthcare Providers. Govt. of India Publication. 2022.

9. Asian Contraception Access Study Group. Barriers to contraceptive implant uptake in low- and middle-income Asian countries: A cross-sectional analysis. Asian J Reprod Med. 2021;19(1):67-74.

10. Bangladesh Ministry of Health. Mobile contraceptive service delivery: Lessons from the Dhaka pilot program. Bangladesh Reproductive Health Review. 2022.

Legend Tables

Table 1: Current Utilization of Norplant in Select Asian Countries

Country	Prevalence (%)	Key Determinants of Use	Primary Distribution Channel
India	2–5	Urban preference, private healthcare	Private clinics, urban hospitals
Indonesia	12	National FP program inclusion	Public health centers
Philippines	8	NGO partnerships	Community health programs
Pakistan	<1	Religious/cultural barriers	Limited to tertiary care centers
Vietnam	6	Government-subsidized programs	District hospitals

Data Sources: National Family Health Surveys (2019–2022), WHO Contraceptive Country Profiles

Table 2: Clinical Advantages vs. Disadvantages of Norplant

Parameter	Advantages	Disadvantages
Efficacy	99.3% effectiveness (5-year protection)	Requires trained provider for insertion
User Control	No daily/user-dependent action	Irreversible once implanted
Metabolic Effects	No estrogen (safe for breastfeeding)	Irregular bleeding (60–70% of users)

Parameter	Advantages	Disadvantages
Cost (India)	₹1,600/year (long-term savings)	High upfront cost (₹8,000–12,000)
Access	Discrete, no clinic visits needed	Limited rural availability (28% coverage)

Evidence: Cochrane Review (2023), ICMR Guidelines (2022)

Table 3: Side Effect Profile from Asian Studies (n=8,214 users)

Side Effect	Prevalence (%)	Management Strategies
Irregular bleeding	68	Low-dose COCs, tranexamic acid
Headaches	22	NSAIDs, implant removal if severe
Weight gain (>5 kg)	15	Lifestyle counseling
Implant site pain	8	Topical analgesics
Mood changes	12	Counseling, alternative contraceptives

Data Sources: Patel et al. (2021), Indonesia FP Program Report (2022)

Table 4: Policy Interventions to Improve Norplant Adoption

Intervention	Example from Asia	Outcome (Study Reference)
Price subsidization	Indonesia’s free implant program	Uptake ↑ 300% in 2 years (Yadav, 2021)
Task-shifting	Bangladesh CHW insertion training	Rural access ↑ 40% (Haque et al., 2022)
Bleeding management protocols	Philippines’ algorithm toolkit	Discontinuation ↓ 35% (Lopez, 2023)
Awareness campaigns	India’s “Plan Your Family” initiative	LARC acceptance ↑ 18% (NHM, 2023)

Table 5: Comparison with Other LARCs

Method	Efficacy (%)	Duration	Cost (India, ₹)	Main Side Effect
Norplant	99.3	5 years	8,000–12,000	Irregular bleeding
Copper IUD	99.2	10 years	1,200–2,500	Heavy menstruation
Injectables	97	3 months	300/dose	Weight gain

Sources: WHO Medical Eligibility Criteria (2022), FOGSI Guidelines (2023)